Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common anesthetic ease severe asthma in kids?

NCT ID NCT07728851

Symptom relief Sponsor: Sultan Qaboos University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether inhaled ketamine can improve breathing in children aged 1 to 13 with severe asthma attacks that do not respond to standard treatments. Participants receive either nebulized ketamine or a placebo every six hours for 24 hours, alongside usual care. The study measures changes in a respiratory distress score and whether children need additional breathing support or longer hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nebulized ketamine
What this could lead to
If effective, nebulized ketamine could offer a new rescue option for children with severe asthma attacks who do not respond to standard therapy, potentially reducing the need for breathing support.
What could go wrong
This is a small early-phase pilot trial, so results may not be conclusive. Ketamine can cause side effects like hallucinations, high blood pressure, or heart rhythm problems, especially in children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 13 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 1 to 13 years. * Diagnosis of severe asthma exacerbation (PRAM score 8-12) * Prior treatment with standard first-line management (beta-2 agonist, corticosteroid, magnesium sulfate) Exclusion Criteria: * Known allergy or adverse reaction to ketamine * Significant hemodynamic instability * Systemic hypertension \>95th percentile for age * Cardiac arrhythmias * Congestive heart failure * Obstructive sleep apnea with AHI \>5

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute asthma allergic asthma asthma status asthmaticus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma acute Exacerbation of allergic asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sultan Qaboos University Hospital

    Muscat, Oman

More trials for these conditions

Other studies related to the condition(s) this trial covers.